BiotechTube
Targepeutics

Targepeutics

Cambridge, United States· Est.
targepeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2M

Overview

Targepeutics is a biotech startup advancing GB-13, a novel targeted immunotoxin, for uniformly fatal brain cancers with dismal survival rates and no new treatments in over 20 years. The company has secured FDA Orphan Drug Designation for GB-13 for GBM and DMG, validating the unmet need and providing regulatory benefits. Led by a small, experienced team with backgrounds in drug development and business, the company is preparing to initiate clinical trials while leveraging non-dilutive grant funding like SBIR awards. Its mission is driven by a personal connection to the disease and a commitment to integrating a new therapeutic into the standard of care.

OncologyNeuro-Oncology

Technology Platform

Targeted immunotoxin platform designed to selectively bind the cancer-associated IL13Rα2 receptor, delivering a cytotoxic payload directly to tumor cells.

Funding History

1
Total raised:$2M
Seed$2M

Opportunities

The primary opportunity lies in addressing a catastrophic unmet need in oncology where survival rates have been static for decades and no new therapies have been approved in over 20 years.
FDA Orphan Drug Designation provides a faster, incentivized regulatory pathway and market exclusivity.
The IL13Rα2-targeting platform could potentially be expanded to other solid tumors expressing the receptor, such as soft tissue sarcomas.

Risk Factors

High clinical risk that preclinical efficacy and safety will not translate to humans, particularly given the challenge of delivering therapeutics across the blood-brain barrier.
Significant financial risk due to dependence on raising substantial capital to fund expensive clinical trials.
Competitive risk from other novel modalities in development for GBM/DMG.

Competitive Landscape

The competitive landscape for GBM/DMG includes other investigational therapies like immunotherapies (CAR-T, checkpoint inhibitors), targeted kinase inhibitors, and viral therapies, though none have yet broken the standard of care. Targepeutics's differentiation is its specific targeting of IL13Rα2 with an immunotoxin payload, a mechanism with limited clinical validation in this space to date.

More companies in Oncology (General) →More companies in United States →